<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21612672</article-id>
      <article-id pub-id-type="pmc">3119071</article-id>
      <article-id pub-id-type="publisher-id">1471-2334-11-152</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2334-11-152</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible <italic>Staphylococcus aureus</italic>: Case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Chen</surname>
            <given-names>Liang-Yu</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>lychen8@vghtpe.gov.tw</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Huang</surname>
            <given-names>Cheng-Hsiung</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>chhuang@vghtpe.gov.tw</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Kuo</surname>
            <given-names>Shu-Chen</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>ludwigvantw@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Hsiao</surname>
            <given-names>Chen-Yuan</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>cyhsiao5@vghtpe.gov.tw</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Lin</surname>
            <given-names>Mei-Lin</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mllin@vghtpe.gov.tw</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A6">
          <name>
            <surname>Wang</surname>
            <given-names>Fu-Der</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>fdwang@vghtpe.gov.tw</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Fung</surname>
            <given-names>Chang-Phone</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>cpfung@vghtpe.gov.tw</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan</aff>
      <aff id="I2"><label>2</label>Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan</aff>
      <aff id="I3"><label>3</label>School of Medicine, National Yang-Ming University, Taipei, Taiwan</aff>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>11</volume>
      <fpage>152</fpage>
      <lpage>152</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>5</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 Chen et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Chen et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2334/11/152"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Emergence of daptomycin-nonsusceptible (DNS) <italic>Staphylococcus aureus </italic>is a dreadful problem in the treatment of endocarditis. Few current therapeutic agents are effective for treating infections caused by DNS <italic>S. aureus</italic>.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We describe the emergence of DNS <italic>S. aureus</italic>. in a patient with implantable cardioverter-defibrillator (ICD) device -related endocarditis who was priorily treated with daptomycin. Metastatic dissemination as osteomyelitis further complicated the management of endocarditis. The dilemma was successfully managed by surgical removal of the ICD device and combination antimicrobial therapy with high-dose daptomycin and fosfomycin.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Surgical removal of intracardiac devices remains an important adjunctive measure in the treatment of endocarditis. Our case suggests that combination therapy is more favorable than single-agent therapy for infections caused by DNS <italic>S. aureus</italic>.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Daptomycin-nonsusceptible</kwd>
        <kwd>fosfomycin</kwd>
        <kwd>ICD device-related endocarditis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Infective endocarditis is a clinically significant disease with mortality ranging from 16% to 25% [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>], and <italic>Staphylococcus aureus </italic>is reported as the most common pathogen, accounting for 31.4% of cases in developing countries [<xref ref-type="bibr" rid="B3">3</xref>]. In addition to methicillin-resistant <italic>S. aureus </italic>(MRSA), the emergence of vancomycin-resistant <italic>S. aureus </italic>also became a major problem after the first report in Japan in 1997 [<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>Daptomycin is a 13-aminoacid compound derived from fermentation of <italic>Streptomyces roseosporus </italic>and is a new treatment option for <italic>S. aureus </italic>endocarditis, including vancomycin-resistant <italic>S. aureus </italic>[<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. The once daily dosing of daptomycin 6 mg/kg approved by the USA Food and Drug administration showed non-inferiority to the standard therapy for treating <italic>S. aureus </italic>bacteremia and endocarditis [<xref ref-type="bibr" rid="B7">7</xref>]. However, increased incidence of daptomycin-nonsusceptible (DNS) <italic>S. aureus </italic>was reported recently. Mutations in the <italic>mprF </italic>and <italic>yycFG </italic>genes, related to membrane fluidity changes or fatty acid biosynthesis, were identified recently as possible contributors to daptomycin nonsusceptibility [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Effective management in case of DNS <italic>S. aureus </italic>infections is an important issue nowadays.</p>
      <p>Fosfomycin, a phosphonic acid derivative (cis-1,2-epoxypropyl phosphonic acid), was initially described and isolated in 1969 from cultures of <italic>Streptomyces </italic>species [<xref ref-type="bibr" rid="B9">9</xref>]. It was commonly employed in treating urinary tract infections and has a bactericidal mechanism of action [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Because it is a relatively small, hydrophilic molecule with almost negligible serum protein binding and good tissue penetration, this agent was more frequently used in combination therapy for treating multidrug-resistant pathogens [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p>
      <p>We present our treatment experience utilizing surgical intervention and high-dose daptomycin in combination with fosfomycin for successful treatment of a patient with implantable cardioverter-defibrillator (ICD) device-related endocarditis complicated with osteomyelitis caused by DNS MRSA.</p>
    </sec>
    <sec>
      <title>Case Presentation</title>
      <p>A 28-year-old woman had a history of sudden onset of syncope diagnosed as paroxysmal ventricular tachycardia. She underwent electric ablation and placement of an ICD in her left shoulder. She had poor wound healing at a 5-month follow-up visit and she was admitted to the hospital on December 1, 2008 for management of a pocket infection. Exposure of the ICD generator and pacing lead were found on February 26, 2009, and the generator was removed, leaving the pacing lead in place. She had episodic pyrexia beginning in May 2009 and her blood cultures grew MRSA (isolate st01, positive in one of two sets blood cultures collected). ICD device-related endocarditis was highly suspected. Intravenous antibiotics with vancomycin 1 g every 12 hours for 14 days followed by oral linezolid 600 mg every 12 hours for another 14 days were prescribed for her endocarditis, but the blood cultures still grew MRSA (isolate st02, positive in one of two sets blood cultures collected). A thoracotomy was planned to remove the pacing lead. However, because of three episodes of broken peripheral venous catheter tips left in the vessels, generator displacement requiring surgical intervention, and emotional fragility, the surgical intervention was postponed due to the high possibility of postoperative wound infection and further osteomyelitis. Daptomycin at a dosage of 6 mg/kg daily was prescribed for its effective biofilm penetration ability and rapid bacteriocidal efficacy, and the subsequent blood culture (one set collected) yielded negative finding. A total 65 days of treatment were completed and the patient was discharged on October 24, 2009.</p>
      <p>Unfortunately, spiking fever and chills occurred 1 day after discharge and the blood cultures grew MRSA again (isolates st03, positive in one of two blood cultures collected). During antibiotic treatment with intravenous tigecycline (100-mg loading dose and 50 mg every 12 hours for 14 days), one of two sets of blood cultures grew MRSA (isolate st04). Teicoplanin 400 mg every 12 hours for another 14 days was given, but another one of two sets of blood cultures grew MRSA (isolate st05). Intravenous daptomycin was prescribed at a dosage of up to 9 mg/kg daily in combination with intravenous fosfomycin 6 g every 6 hours starting December 16, 2009, due to the persistence of MRSA bacteremia with the ICD device in place. The patient's fever subsided after these treatments and the next three sets of blood cultures were negative 1 week after the start of daptomycin-fosfomycin combination therapy. However, transesophageal echocardiography revealed vegetations growing on the pacing lead, and a scan for osteomyelitis showed increased uptake of the radiotracer in the left proximal clavicle. Moreover, the daptomycin Etest (AB Biodisk, Solna, Sweden) of MRSA isolate st05 indicated that it was nonsusceptible to daptomycin, with a minimal inhibitory concentration (MIC) ranging from 1.5 to 2 mg/L. After discussion among the surgeons and infectious disease specialists, a thoracotomy was performed on December 22, 2009 for removal of the pacing lead due to the previous persistence of <italic>S. aureus </italic>bacteremia; high-dose daptomycin 12 mg/kg intravenously daily was also started. A vegetation measuring 1.3 &#xD7; 0.6 &#xD7; 0.1 cm was found on the pacing lead, but the Gram stain showed no microbes. Tissue culture of the vegetation found on the pacing lead grew MRSA (isolate st06), as did as the tip of the pacing lead (isolate st07).</p>
      <p>Because the osteomyelitis scan was positive, combination therapy with daptomycin 12 mg/kg intravenously daily and fosfomycin 6 g intravenously every 6 hours was administered for total of 56 days. The patient had no further pyretic episodes following hospitalization. A follow-up osteomyelitis scan on March 8, 2010 was negative, and follow-up transthoracic echocardiography showed no vegetation. The patient's symptoms were attributed to endocarditis; she remained symptom free during 12 months of follow-up.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>The species identification was completed using the API 32GN biochemical testing system (bioM&#xE9;rieux, Inc., Marcy l'&#xC9;toile, France). Antimicrobial susceptibility testing was performed using agar dilution method with 25 mg/L glucose-6 phosphate added for fosfomycin testing; the broth dilution method of antimicrobial susceptibility testing was used for the other antimicrobial agents, as specified by the Clinical Laboratory Standards Institute (CLSI 2010), using the VITEK<sup>&#xAE; </sup>2 Compact system (bioM&#xE9;rieux, Inc.,) and daptomycin Etest strips (AB Biodisk, Solna, Sweden). Guidance for interpreting the MICs as clinical categories (susceptible, intermediate, or resistant) was provided by the manufacturer's instructions and CLSI criteria. Isolates with daptomycin MICs &#x2264; 1 mg/L were defined as daptomycin-susceptible, and those with MICs &gt; 1 mg/L were defined as daptomycin-nonsusceptible. No MIC interpretation criteria were available for fosfomycin on bacteremia in CLSI criteria, but isolates with MICs less than 32 mg/L were defined as susceptible by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). In order to establish the clonality of these isolates, we performed pulsed-field gel electrophoresis (PFGE) as described previously [<xref ref-type="bibr" rid="B12">12</xref>]. <italic>S. aureus </italic>ATCC 29213 was used as the quality control organism.</p>
    </sec>
    <sec>
      <title>Results</title>
      <p>The seven isolates were analyzed by their Sma1 PFGE profiles and isolates st02 to st06 showed the same profile, while isolates st01 and st07 were different. Progressive elevation of the daptomycin MICs for isolates of the same clonality occurred, but decreasing MICs for isolate st06 were noted for vancomycin, teicoplanin, and daptomycin compared to those of isolate st05 (Table <xref ref-type="table" rid="T1">1</xref>). The MICs of fosfomycin for all isolates were less than 2 mg/L by the agar dilution methods and showed susceptibility based on the EUCAST criteria. All isolates were resistant to the other antimicrobials screened using the VITEK<sup>&#xAE; </sup>2 Compact system (Table <xref ref-type="table" rid="T1">1</xref>).</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Antimicrobial susceptibility results for the seven methicillin-resistant <italic>Staphylococcus aureus </italic>clinical isolates</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left">Isolate</th>
              <th align="left">Date of isolation</th>
              <th align="center" colspan="8">MIC (mg/L)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td/>
              <td/>
              <td align="center" colspan="3">
                <bold>Vitek 2</bold>
              </td>
              <td align="center" colspan="3">
                <bold>Broth dilution</bold>
              </td>
              <td align="center">
                <bold>Agar dilution</bold>
              </td>
              <td align="center">
                <bold>Etest</bold>
              </td>
            </tr>
            <tr>
              <td colspan="10">
                <hr/>
              </td>
            </tr>
            <tr>
              <td/>
              <td/>
              <td align="center">
                <bold>VAN</bold>
              </td>
              <td align="center">
                <bold>TEIC</bold>
              </td>
              <td align="center">
                <bold>LIN</bold>
              </td>
              <td align="center">
                <bold>VAN</bold>
              </td>
              <td align="center">
                <bold>TEIC</bold>
              </td>
              <td align="center">
                <bold>DPC</bold>
              </td>
              <td align="center">
                <bold>FOS</bold>
              </td>
              <td align="center">
                <bold>DPC</bold>
              </td>
            </tr>
            <tr>
              <td colspan="10">
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left">st01</td>
              <td align="left">2009/5/19</td>
              <td align="center">&lt; 0.5</td>
              <td align="center">&lt; 0.5</td>
              <td align="center">2</td>
              <td align="center">1</td>
              <td align="center">1</td>
              <td align="center">0.25</td>
              <td align="center">&lt; 2</td>
              <td align="center">0.19</td>
            </tr>
            <tr>
              <td align="left">st02</td>
              <td align="left">2009/9/27</td>
              <td align="center">2</td>
              <td align="center">&lt; 0.5</td>
              <td align="center">2</td>
              <td align="center">1</td>
              <td align="center">1</td>
              <td align="center">0.25</td>
              <td align="center">&lt; 2</td>
              <td align="center">0.38</td>
            </tr>
            <tr>
              <td align="left">st03</td>
              <td align="left">2009/10/29</td>
              <td align="center">2</td>
              <td align="center">&lt; 0.5</td>
              <td align="center">4</td>
              <td align="center">1</td>
              <td align="center">1</td>
              <td align="center">0.5</td>
              <td align="center">&lt; 2</td>
              <td align="center">0.25</td>
            </tr>
            <tr>
              <td align="left">st04</td>
              <td align="left">2009/11/10</td>
              <td align="center">1</td>
              <td align="center">&lt; 0.5</td>
              <td align="center">4</td>
              <td align="center">1</td>
              <td align="center">1</td>
              <td align="center">0.5</td>
              <td align="center">&lt; 2</td>
              <td align="center">0.25</td>
            </tr>
            <tr>
              <td align="left">st05</td>
              <td align="left">2009/12/11</td>
              <td align="center">2</td>
              <td align="center">2</td>
              <td align="center">4</td>
              <td align="center">2</td>
              <td align="center">0.25</td>
              <td align="center">1</td>
              <td align="center">&lt; 2</td>
              <td align="center">1.5-2</td>
            </tr>
            <tr>
              <td align="left">st06</td>
              <td align="left">2009/12/22</td>
              <td align="center">2</td>
              <td align="center">&lt; 0.5</td>
              <td align="center">2</td>
              <td align="center">1</td>
              <td align="center">0.5</td>
              <td align="center">0.5</td>
              <td align="center">&lt; 2</td>
              <td align="center">0.25</td>
            </tr>
            <tr>
              <td align="left">st07</td>
              <td align="left">2009/12/22</td>
              <td align="center">2</td>
              <td align="center">1</td>
              <td align="center">4</td>
              <td align="center">2</td>
              <td align="center">4</td>
              <td align="center">2</td>
              <td align="center">&lt; 2</td>
              <td align="center">1</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>DPC: daptomycin; FOS: fosfomycin; LIN: linezolid; MIC: minimal inhibitory concentration; TEIC: teicoplanin; VAN: vancomycin</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec>
      <title>Conclusions</title>
      <p>Combination therapy consisting of high-dose daptomycin and fosfomycin is an alternative treatment option for DNS MRSA native valve endocarditis or osteomyelitis. These two agents are well known for their bacteriocidal activities and effective biofilm penetration [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Recently, positive results for fosfomycin used in combination with other antimicrobial agents against multidrug resistant Gram-positive pathogens were also reported [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p>
      <p>Isolate st06 from the vegetation, of the same clonality as isolate st05, was susceptible to vancomycin, teicoplanin, and daptomycin in combination with fosfomycin with additive effect. Additionally, the pathological findings of the vegetation were negative for microbes, which suggested that the combination regimen was highly effective in biofilm penetration and killing the bacteria. Moreover, the osteomyelitis was successfully treated in 8 weeks, without complications. Although high-dose daptomycin treatment could be effective after surgical removal of an ICD-device for adequate pharmacodynamics attainments, the combination therapy is preferred in complicated cases, and further study to establish the adequate combination dosage of daptomycin with fosfomycin is needed. Steed et al. also reported that the combination of daptomycin plus clotrimoxazole was bactericidal against DNS MRSA in an in vitro model of simulated endocardial vegetations [<xref ref-type="bibr" rid="B13">13</xref>].</p>
      <p>High-dose daptomycin treatment (12 mg/kg daily) was well tolerated in our patient throughout the 8-week treatment course. In a previous study, patients received daptomycin in dosages greater than 8 mg/kg per day, and 79% of patients were considered evaluable for efficacy; only 6.4% experienced 1 or more adverse events or abnormal laboratory analyte values [<xref ref-type="bibr" rid="B14">14</xref>]. Another recent report also revealed no remarkable creatinine kinase elevation after daptomycin use in dosage greater than 8 mg/kg once daily for a prolonged course of 14 days [<xref ref-type="bibr" rid="B15">15</xref>]. Because the resistance mechanism of <italic>S. aureus </italic>to daptomycin is unique in comparison to other glycopeptides, and every single gene mutation, such as <italic>mprF </italic>and <italic>yycFG </italic>genes, causes only a slight increase in daptomycin MIC, higher doses of daptomycin could still be effective for the treatment of DNS <italic>S. aureus </italic>[<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Nonetheless, in vitro and in vivo evidence suggests that combination therapy is more favorable than single-agent therapy for infections caused by DNS <italic>S. aureus</italic>, and antibiotic therapy must be individualized for each patient's condition.</p>
      <p>For patients with ICD device-related endocarditis, surgical removal of the device is strongly recommended when <italic>S. aureus </italic>bacteremia persists after antimicrobial therapy [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. As reported by del Rio A et al. the prevalence of treatment failure is greater among patients receiving only antibiotics therapy compared to those treated with surgical removal of implanted device and antibiotics therapy [<xref ref-type="bibr" rid="B18">18</xref>]. Recurrence of MRSA bacteremia identified during our patient's second visit suggested treatment failure, even though the blood cultures were negative after the initial daptomycin treatment; such patients should undergo prompt surgical removal of the ICD device. It is possible that with daptomycin alone the patient could have been cured in the first attempt if the ICD lead had been surgical removed. Although the combination therapy achieved negative blood cultures, the tissue culture of the vegetation and pacing lead still grew MRSA, with isolate st07 showing increased daptomycin resistance. Recurrence would have remained possible without the removal of the pacing lead.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>LYC, SCK, and MLL completed the microbial cultures, agar and broth microdilutions for MICs and PFGE. CHH and CYH took responsibility of the patient on admission for wound debridement, thoracotomy, and postsurgical care. FDW and CPF suggested and decided which antibiotics were administered and suggested the plan of action based on the advanced image examinations. All authors read and approved the manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/11/152/prepub">http://www.biomedcentral.com/1471-2334/11/152/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>We thank Mr. Chi-Chung Chen (E-mail address: ccomm2@yahoo.com.tw) from Department of Internal Medicine, Medical Research, Chi Mei Medical Center, Tainan, Taiwan, for his technique support on antimicrobial susceptibility tests.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Moreillon</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Que</surname>
            <given-names>YA</given-names>
          </name>
          <article-title>Infective endocarditis</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>363</volume>
          <fpage>139</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(03)15266-X</pub-id>
          <pub-id pub-id-type="pmid">14726169</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mylonakis</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Calderwood</surname>
            <given-names>SB</given-names>
          </name>
          <article-title>Infective endocarditis in adults</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>345</volume>
          <fpage>1318</fpage>
          <lpage>1330</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra010082</pub-id>
          <pub-id pub-id-type="pmid">11794152</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fowler</surname>
            <given-names>VG</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Miro</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Hoen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Cabell</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Abrutyn</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Rubinstein</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Corey</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Spelman</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bradley</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Barsic</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
          <article-title><italic>Staphylococcus aureus </italic>endocarditis: a consequence of medical progress</article-title>
          <source>JAMA</source>
          <year>2005</year>
          <volume>293</volume>
          <fpage>3012</fpage>
          <lpage>3021</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.293.24.3012</pub-id>
          <pub-id pub-id-type="pmid">15972563</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hiramatsu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hanaki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ino</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yabuta</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Oguri</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Tenover</surname>
            <given-names>FC</given-names>
          </name>
          <article-title>Methicillin-resistant <italic>Staphylococcus aureus </italic>clinical strain with reduced vancomycin susceptibility</article-title>
          <source>J Antimicrob Chemother</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>135</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/40.1.135</pub-id>
          <pub-id pub-id-type="pmid">9249217</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Baltz</surname>
            <given-names>RH</given-names>
          </name>
          <article-title>Daptomycin: mechanisms of action and resistance, and biosynthetic engineering</article-title>
          <source>Curr Opin Chem Biol</source>
          <year>2009</year>
          <volume>13</volume>
          <fpage>144</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cbpa.2009.02.031</pub-id>
          <pub-id pub-id-type="pmid">19303806</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Falagas</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Giannopoulou</surname>
            <given-names>KP</given-names>
          </name>
          <name>
            <surname>Ntziora</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Vardakas</surname>
            <given-names>KZ</given-names>
          </name>
          <article-title>Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence</article-title>
          <source>J Antimicrob Chemother</source>
          <year>2007</year>
          <volume>60</volume>
          <fpage>7</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="doi">10.1093/jac/dkm137</pub-id>
          <pub-id pub-id-type="pmid">17550889</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fowler</surname>
            <given-names>VG</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Boucher</surname>
            <given-names>HW</given-names>
          </name>
          <name>
            <surname>Corey</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Abrutyn</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Karchmer</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Rupp</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Chambers</surname>
            <given-names>HF</given-names>
          </name>
          <name>
            <surname>Tally</surname>
            <given-names>FP</given-names>
          </name>
          <name>
            <surname>Vigliani</surname>
            <given-names>GA</given-names>
          </name>
          <etal/>
          <article-title>Daptomycin versus standard therapy for bacteremia and endocarditis caused by <italic>Staphylococcus aureus</italic></article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>355</volume>
          <fpage>653</fpage>
          <lpage>665</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa053783</pub-id>
          <pub-id pub-id-type="pmid">16914701</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jones</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yeaman</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Sakoulas</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Proctor</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Sahl</surname>
            <given-names>HG</given-names>
          </name>
          <name>
            <surname>Schrenzel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Xiong</surname>
            <given-names>YQ</given-names>
          </name>
          <name>
            <surname>Bayer</surname>
            <given-names>AS</given-names>
          </name>
          <article-title>Failures in clinical treatment of <italic>Staphylococcus aureus </italic>Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2008</year>
          <volume>52</volume>
          <fpage>269</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.00719-07</pub-id>
          <pub-id pub-id-type="pmid">17954690</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Falagas</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Giannopoulou</surname>
            <given-names>KP</given-names>
          </name>
          <name>
            <surname>Kokolakis</surname>
            <given-names>GN</given-names>
          </name>
          <name>
            <surname>Rafailidis</surname>
            <given-names>PI</given-names>
          </name>
          <article-title>Fosfomycin: use beyond urinary tract and gastrointestinal infections</article-title>
          <source>Clin Infect Dis</source>
          <year>2008</year>
          <volume>46</volume>
          <fpage>1069</fpage>
          <lpage>1077</lpage>
          <pub-id pub-id-type="doi">10.1086/527442</pub-id>
          <pub-id pub-id-type="pmid">18444827</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Roussos</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Karageorgopoulos</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Samonis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Falagas</surname>
            <given-names>ME</given-names>
          </name>
          <article-title>Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections</article-title>
          <source>Int J Antimicrob Agents</source>
          <year>2009</year>
          <volume>34</volume>
          <fpage>506</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.08.013</pub-id>
          <pub-id pub-id-type="pmid">19828298</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Falagas</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Roussos</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Gkegkes</surname>
            <given-names>ID</given-names>
          </name>
          <name>
            <surname>Rafailidis</surname>
            <given-names>PI</given-names>
          </name>
          <name>
            <surname>Karageorgopoulos</surname>
            <given-names>DE</given-names>
          </name>
          <article-title>Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies</article-title>
          <source>Expert Opin Investig Drugs</source>
          <year>2009</year>
          <volume>18</volume>
          <fpage>921</fpage>
          <lpage>944</lpage>
          <pub-id pub-id-type="doi">10.1517/13543780902967624</pub-id>
          <pub-id pub-id-type="pmid">19548851</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Murchan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kaufmann</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Deplano</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>de Ryck</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Struelens</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zinn</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Fussing</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Salmenlinna</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vuopio-Varkila</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>El Solh</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
          <article-title>Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant <italic>Staphylococcus aureus</italic>: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains</article-title>
          <source>J Clin Microbiol</source>
          <year>2003</year>
          <volume>41</volume>
          <fpage>1574</fpage>
          <lpage>1585</lpage>
          <pub-id pub-id-type="doi">10.1128/JCM.41.4.1574-1585.2003</pub-id>
          <pub-id pub-id-type="pmid">12682148</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Steed</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Vidaillac</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rybak</surname>
            <given-names>MJ</given-names>
          </name>
          <article-title>Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant <italic>Staphylococcus aureus </italic>in an in vitro model of simulated endocardial vegetations</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2010</year>
          <volume>54</volume>
          <fpage>5187</fpage>
          <lpage>5192</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.00536-10</pub-id>
          <pub-id pub-id-type="pmid">20921318</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Moise</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Hershberger</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Amodio-Groton</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Lamp</surname>
            <given-names>KC</given-names>
          </name>
          <article-title>Safety and clinical outcomes when utilizing high-dose (&gt; or = 8 mg/kg) daptomycin therapy</article-title>
          <source>Ann Pharmacother</source>
          <year>2009</year>
          <volume>43</volume>
          <fpage>1211</fpage>
          <lpage>1219</lpage>
          <pub-id pub-id-type="doi">10.1345/aph.1M085</pub-id>
          <pub-id pub-id-type="pmid">19584384</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Figueroa</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Mangini</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Amodio-Groton</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Vardianos</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Melchert</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fana</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wehbeh</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Urban</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Segal-Maurer</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program</article-title>
          <source>Clin Infect Dis</source>
          <year>2009</year>
          <volume>49</volume>
          <fpage>177</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="doi">10.1086/600039</pub-id>
          <pub-id pub-id-type="pmid">19500039</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Baddour</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Epstein</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Erickson</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Knight</surname>
            <given-names>BP</given-names>
          </name>
          <name>
            <surname>Levison</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Lockhart</surname>
            <given-names>PB</given-names>
          </name>
          <name>
            <surname>Masoudi</surname>
            <given-names>FA</given-names>
          </name>
          <name>
            <surname>Okum</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>WR</given-names>
          </name>
          <name>
            <surname>Beerman</surname>
            <given-names>LB</given-names>
          </name>
          <etal/>
          <article-title>Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association</article-title>
          <source>Circulation</source>
          <year>2010</year>
          <volume>121</volume>
          <fpage>458</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.192665</pub-id>
          <pub-id pub-id-type="pmid">20048212</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Baddour</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>WR</given-names>
          </name>
          <name>
            <surname>Bayer</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Fowler</surname>
            <given-names>VG</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Bolger</surname>
            <given-names>AF</given-names>
          </name>
          <name>
            <surname>Levison</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Ferrieri</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gerber</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Tani</surname>
            <given-names>LY</given-names>
          </name>
          <name>
            <surname>Gewitz</surname>
            <given-names>MH</given-names>
          </name>
          <etal/>
          <article-title>Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America</article-title>
          <source>Circulation</source>
          <year>2005</year>
          <volume>111</volume>
          <fpage>e394</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.165564</pub-id>
          <pub-id pub-id-type="pmid">15956145</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>del Rio</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Anguera</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Miro</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Mont</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Fowler</surname>
            <given-names>VG</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Azqueta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Mestres</surname>
            <given-names>CA</given-names>
          </name>
          <article-title>Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome</article-title>
          <source>Chest</source>
          <year>2003</year>
          <volume>124</volume>
          <fpage>1451</fpage>
          <lpage>1459</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.124.4.1451</pub-id>
          <pub-id pub-id-type="pmid">14555579</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
